Skip to main content
. 2024 Aug 2;131(6):1060–1067. doi: 10.1038/s41416-024-02804-6

Fig. 4. CDK4 amplification analysis in ER + /HER2- mBC and ER + /HER2− eBC.

Fig. 4

a CDK4 amplification frequency (%) in ER + /HER2− mBC patients treated or not by CDK4/6i before samples collection and in ER + /HER2− eBC patients. b CDK4 RNA expression by real-time quantitative RT-PCR stratified according the CDK4 amplification status in ER + /HER2− mBC population. c Overall survival in univariable analysis in ER + /HER2− eBC. d Overall survival in multivariable analysis in ER + /HER2− eBC.